Abadan, Romel G.
HRN: 20-83-70 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/03/2024
OXACILLIN 500MG (VIAL)
01/03/2024
01/10/2024
IV
250mg
Q6hours
Cellulitis
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes